CorWave has announced the world’s first human implantation of its novel left ventricular assist device (LVAD) featuring wave membrane technology. The milestone procedure was performed at St. Vincent’s Hospital in Sydney, Australia, on a patient with advanced heart failure, who has since met the 30-day survival endpoint without device-related complications and reports significant symptom relief.
Inspired by the swimming motion of aquatic animals, CorWave’s membrane pump aims to mimic natural heart function by automatically adjusting blood flow with each heartbeat, unlike conventional rotary LVADs that provide fixed flow. The French company says this design may reduce complications such as stroke and bleeding, while preserving cardiac structure and promoting recovery. Abbott’s HeartMate 3 currently remains the only FDA-approved LVAD on the market in the U.S.
Follow MEDWIRE.AI for breakthroughs in heart failure technologies.
